{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:03:53Z","timestamp":1792843433678,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1173791"],"award-info":[{"award-number":["1173791"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2011100"],"award-info":[{"award-number":["2011100"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cmi.2024.08.006","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T01:58:26Z","timestamp":1723427906000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges"],"prefix":"10.1016","volume":"31","author":[{"given":"Maddalena","family":"Giannella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Lanternier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Delli\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas J.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Alastruey-Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.08.006_bib1","series-title":"WHO Fungal Priority Pathogens List to guide research, development and public health action","year":"2022"},{"key":"10.1016\/j.cmi.2024.08.006_bib2","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib3","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","article-title":"Changes in prevalence of health care-associated infections in U.S. hospitals","volume":"379","author":"Magill","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.08.006_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00873-23","article-title":"A\u00a0conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC","volume":"61","author":"de Hoog","year":"2023","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2024.08.006_bib5","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","article-title":"Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis","volume":"25","author":"Koehler","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.08.006_bib6","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/cid\/civ293","article-title":"Epidemiology and outcome of fungemia in a cancer cohort of the infectious diseases group (IDG) of the European organization for research and treatment of cancer (EORTC 65031)","volume":"61","author":"Cornely","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib7","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/myc.13130","article-title":"Candidaemia in haematological malignancy patients from a SEIFEM study: epidemiological patterns according to antifungal prophylaxis","volume":"63","author":"Posteraro","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2024.08.006_bib8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/INF.0000000000002530","article-title":"Etiology and outcome of candidemia in neonates and children in Europe: an 11-year multinational retrospective study","volume":"39","author":"Warris","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2024.08.006_bib9","first-page":"994","article-title":"Comparative effectiveness of echinocandins vs triazoles or amphotericin B formulations as initial directed therapy for invasive candidiasis in children and adolescents","volume":"10","author":"Fisher","year":"2021","journal-title":"J\u00a0Pediatr Infect Dis Soc"},{"key":"10.1016\/j.cmi.2024.08.006_bib10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.15585\/mmwr.mm7029a2","article-title":"Notes from the field: transmission of pan-resistant and echinocandin-resistant Candida auris in health care facilities \u2013 Texas and the District of Columbia, January\u2013April 2021","volume":"70","author":"Lyman","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2024.08.006_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03540-23","article-title":"Emergence of the novel sixth Candida auris Clade VI in Bangladesh","volume":"12","author":"Khan","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2024.08.006_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012011","article-title":"The many faces of Candida auris: phenotypic and strain variation in an emerging pathogen","volume":"20","author":"Santana","year":"2024","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cmi.2024.08.006_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011698","article-title":"Tools and techniques to identify, study, and control Candida auris","volume":"19","author":"Carty","year":"2023","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cmi.2024.08.006_bib14","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3390\/antibiotics9110778","article-title":"Candida auris: an overview of how to screen, detect, test and control this emerging pathogen","volume":"9","author":"Fasciana","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2024.08.006_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac605","article-title":"Global emergence of resistance to fluconazole and voriconazole in Candida parapsilosis in tertiary hospitals in Spain during the COVID-19 pandemic","volume":"9","author":"Trevijano-Contador","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib16","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2666-5247(23)00067-8","article-title":"Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap","volume":"4","author":"Daneshnia","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.cmi.2024.08.006_bib17","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1128\/JCM.01130-12","article-title":"In\u00a0vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study","volume":"50","author":"Wang","year":"2012","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2024.08.006_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1125241","article-title":"High prevalence of fluconazole resistant Candida tropicalis among candiduria samples in China: an ignored matter of concern","volume":"14","author":"Fan","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2024.08.006_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlab122","article-title":"Emergence of resistant Candida glabrata in Germany","volume":"3","author":"Aldejohann","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2024.08.006_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009503","article-title":"Climate change and the emergence of fungal pathogens","volume":"17","author":"Nnadi","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cmi.2024.08.006_bib21","article-title":"Cryptococcus neoformans infections differ among (HIV)-seropositive and HIV-seronegative individuals: results from a nationwide surveillance program in France","volume":"11","author":"Paccoud","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib22","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/cid\/ciad321","article-title":"Current epidemiology and clinical features of Cryptococcus infection in patients without human immunodeficiency virus: a multicenter study in 46 hospitals in Australia and New Zealand","volume":"77","author":"Coussement","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib23","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: Summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.08.006_bib24","first-page":"1079","article-title":"Invasive aspergillosis among lung transplant recipients during time periods with universal and targeted antifungal prophylaxis \u2013 a nationwide cohort study","volume":"9","author":"Crone","year":"2023","journal-title":"J\u00a0Fungi (Basel)"},{"key":"10.1016\/j.cmi.2024.08.006_bib25","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/cid\/ciy473","article-title":"Breakthrough invasive mold infections in the hematology patient: current concepts and future directions","volume":"67","author":"Lionakis","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib26","article-title":"Invasive aspergillosis in adult patients in Australia and New Zealand: 2017\u20132020","volume":"40","author":"Tio","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.cmi.2024.08.006_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12660","article-title":"Invasive fungal infections in solid organ transplant recipients","volume":"20","author":"Gavald\u00e0","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.08.006_bib28","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.3324\/haematol.2014.114025","article-title":"Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies","volume":"100","author":"Teh","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2024.08.006_bib29","article-title":"Risk of infection associated with targeted therapies for solid organ and hematological malignancies","volume":"8","author":"Ruiz-Camps","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00920-22","article-title":"Active surveillance program to increase awareness on invasive fungal diseases: the French RESSIF Network (2012 to 2018)","volume":"13","author":"Bretagne","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2024.08.006_bib31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/cid\/ciad546","article-title":"High burden of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in severely immunocompromised patients requiring mechanical ventilation","volume":"78","author":"Feys","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib32","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41579-023-00960-9","article-title":"The rapid emergence of antifungal-resistant human-pathogenic fungi","volume":"21","author":"Lockhart","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2024.08.006_bib33","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.1093\/infdis\/jix210","article-title":"Azole-resistant aspergillosis: epidemiology, molecular mechanisms, and treatment","volume":"216","author":"Chowdhary","year":"2017","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib34","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study","volume":"68","author":"Lestrade","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib35","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/jac\/dkz258","article-title":"Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients","volume":"74","author":"Resendiz-Sharpe","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.08.006_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.mmcr.2022.02.002","article-title":"Selection of Aspergillus fumigatus isolates carrying the G448S substitution in CYP51A gene after long-term treatment with voriconazole in an immunocompromised patient","volume":"36","author":"Pontes","year":"2022","journal-title":"Med Mycol Case Rep"},{"key":"10.1016\/j.cmi.2024.08.006_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/cid\/ciad141","article-title":"Clinical impact of polymerase chain reaction-based Aspergillus and azole resistance detection in invasive aspergillosis: a prospective multicenter study","volume":"77","author":"Huygens","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib38","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.08.006_bib39","first-page":"212","article-title":"Non-Aspergillus hyaline molds: a host-based perspective of emerging pathogenic fungi causing sinopulmonary diseases","volume":"9","author":"Jacobs","year":"2023","journal-title":"J\u00a0Fungi (Basel)"},{"key":"10.1016\/j.cmi.2024.08.006_bib40","first-page":"848","article-title":"Changing epidemiology of invasive fungal disease in allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Puerta-Alcalde","year":"2021","journal-title":"J\u00a0Fungi"},{"key":"10.1016\/j.cmi.2024.08.006_bib41","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.chest.2023.06.039","article-title":"Improving diagnosis of pulmonary mucormycosis: leads from a contemporary national study of 114 cases","volume":"164","author":"Coste","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2024.08.006_bib42","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/myc.13205","article-title":"Epidemiology of invasive fungal disease in haematologic patients","volume":"64","author":"Souza","year":"2021","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2024.08.006_bib43","doi-asserted-by":"crossref","first-page":"490.e1","DOI":"10.1016\/j.cmi.2014.12.021","article-title":"Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality","volume":"21","author":"Slavin","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.08.006_bib44","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2141.2009.08072.x","article-title":"Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant","volume":"149","author":"Hale","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2024.08.006_bib46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jpids\/piu074","article-title":"A\u00a0prospective, international cohort study of invasive mold infections in children","volume":"4","author":"Wattier","year":"2015","journal-title":"J\u00a0Pediatr Infect Dis Soc"},{"key":"10.1016\/j.cmi.2024.08.006_bib47","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/pix046","article-title":"Epidemiology of invasive fungal disease in children","volume":"6","author":"Pana","year":"2017","journal-title":"J\u00a0Pediatr Infect Dis Soc"},{"key":"10.1016\/j.cmi.2024.08.006_bib48","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2024.08.006_bib49","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/pbc.23005","article-title":"Invasive fungal infections in pediatric oncology","volume":"56","author":"Mor","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.cmi.2024.08.006_bib50","first-page":"783","article-title":"Outbreak-causing fungi: Pneumocystis jirovecii","volume":"185","author":"Delli\u00e8re","year":"2020","journal-title":"Mycopathologia"},{"key":"10.1016\/j.cmi.2024.08.006_bib51","first-page":"466","article-title":"Projecting the medical costs of AIDS and ARC in the United States","volume":"1","author":"Hay","year":"1988","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2024.08.006_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s13054-023-04608-1","article-title":"Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG","volume":"27","author":"Giacobbe","year":"2023","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2024.08.006_bib53","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.mayocp.2020.07.029","article-title":"Host factors and outcomes in hospitalizations for Pneumocystis jirovecii pneumonia in the United States","volume":"96","author":"Kanj","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cmi.2024.08.006_bib54","doi-asserted-by":"crossref","first-page":"739","DOI":"10.12688\/f1000research.10619.1","article-title":"Pneumocystis jirovecii detection in asymptomatic patients: what does its natural history tell us?","volume":"6","author":"Alanio","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.cmi.2024.08.006_bib55","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib56","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1097\/INF.0000000000004102","article-title":"Prevention, diagnosis and management of Pneumocystis jirovecii infection in children with cancer or receiving hematopoietic cell therapy","volume":"42","author":"Cross","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2024.08.006_bib57","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1111\/bjh.19382","article-title":"Pneumocystis jirovecii pneumonia in paediatric acute lymphoblastic leukaemia: a report from the Multi-international Clinical Trial AIEOP-BFM ALL 2009","volume":"204","author":"Barnbrock","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2024.08.006_bib58","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/cid\/civ299","article-title":"Histoplasmosis complicating tumor necrosis factor-\u03b1 blocker therapy: a retrospective analysis of 98 cases","volume":"61","author":"Vergidis","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib59","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz073","article-title":"Histoplasmosis, an underdiagnosed disease affecting people living with HIV\/AIDS in Brazil: results of a multicenter prospective cohort study using both classical mycology tests and histoplasma urine antigen detection","volume":"6","author":"Falci","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006046","article-title":"Histoplasmosis in Africa: an emerging or a neglected disease?","volume":"12","author":"Oladele","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib61","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac368","article-title":"Prevalence of histoplasmosis and molecular characterization of histoplasma species in patients with presumptive pulmonary tuberculosis in Calabar, Nigeria","volume":"9","author":"Ekeng","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib62","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1215460","article-title":"A\u00a0dimorphic fungus causing disseminated infection in South Africa","volume":"369","author":"Kenyon","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.08.006_bib63","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1128\/JCM.02524-16","article-title":"In\u00a0vitro antifungal susceptibility of yeast and mold phases of isolates of dimorphic fungal pathogen Emergomyces africanus (formerly Emmonsia sp.) from HIV-infected South African patients","volume":"55","author":"Maphanga","year":"2017","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2024.08.006_bib64","article-title":"Development and validation of a new quantitative reverse transcription PCR assay for the diagnosis of human sporotrichosis","volume":"61","author":"Marques de Macedo","year":"2023","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2024.08.006_bib65","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jmoldx.2021.02.007","article-title":"Evaluation of a new Histoplasma spp. quantitative RT-PCR assay","volume":"23","author":"Alanio","year":"2021","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.cmi.2024.08.006_bib66","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1029\/2019GH000209","article-title":"Expansion of coccidioidomycosis endemic regions in the United States in response to climate change","volume":"3","author":"Gorris","year":"2019","journal-title":"GeoHealth"},{"key":"10.1016\/j.cmi.2024.08.006_bib67","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/cid\/cis1028","article-title":"Coccidioidomycosis acquired in Washington state","volume":"56","author":"Marsden-Haug","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib68","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00051-22","article-title":"An overlooked and underrated endemic mycosis-talaromycosis and the pathogenic fungus Talaromyces marneffei","volume":"36","author":"Wang","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2024.08.006_bib69","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14787210.2023.2203383","article-title":"The antifungal pipeline for invasive fungal diseases: what does the future hold?","volume":"21","author":"Neoh","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cmi.2024.08.006_bib70","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/jac\/dkad256","article-title":"Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial","volume":"78","author":"Pappas","year":"2023","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.08.006_bib71","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01419-22","article-title":"Clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by Candida auris: results from a phase 2 trial","volume":"67","author":"Vazquez","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.006_bib72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2024.08.006_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106105","article-title":"In\u00a0vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus","volume":"56","author":"Kirchhoff","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.08.006_bib74","series-title":"In\u00a0vitro activity of olorofim against clinically relevant filamentous fungi from French reference centre for invasive mycosis and antifungals [accepted abstract \u2013 Poster number E0594]. ECCMID 2023. Denmark, Copenhagen","author":"Garcia-Hermoso","year":"2023"},{"key":"10.1016\/j.cmi.2024.08.006_bib75","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.006_bib76","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In\u00a0vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.006_bib77","doi-asserted-by":"crossref","first-page":"e00178","DOI":"10.1128\/AAC.00178-20","article-title":"Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to rhizopus arrhizus","volume":"64","author":"Gebremariam","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.006_bib78","doi-asserted-by":"crossref","first-page":"e01795","DOI":"10.1128\/AAC.01795-20","article-title":"Efficacy and pharmacokinetics of fosmanogepix (APX001) in the treatment of candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits","volume":"65","author":"Petraitiene","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.006_bib79","doi-asserted-by":"crossref","first-page":"e01692","DOI":"10.1128\/AAC.01692-19","article-title":"In\u00a0vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations","volume":"63","author":"Nunnally","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.006_bib80","doi-asserted-by":"crossref","first-page":"e00161","DOI":"10.1128\/AAC.00161-17","article-title":"Differential activity of the oral glucan synthase inhibitor scy-078 against wild-type and echinocandin-resistant strains of Candida species","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.006_bib81","doi-asserted-by":"crossref","first-page":"S643","DOI":"10.1093\/ofid\/ofaa439.1435","article-title":"1251. Prevention of Pneumocystis pneumonia by ibrexafungerp in a murine prophylaxis model","volume":"7","author":"Borroto-Esoda","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.006_bib82","doi-asserted-by":"crossref","first-page":"e01992","DOI":"10.1128\/AAC.01992-20","article-title":"Efficacy of rezafungin in prophylactic mouse models of invasive candidiasis, aspergillosis, and Pneumocystis pneumonia","volume":"65","author":"Miesel","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24003860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24003860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:09:46Z","timestamp":1767240586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24003860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1198743X24003860"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.08.006","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}